<DOC>
	<DOCNO>NCT00110890</DOCNO>
	<brief_summary>The purpose study evaluate ability treatment strategy , include cinacalcet management secondary hyperparathyroidism , control parathyroid hormone ( PTH ) compare standard care .</brief_summary>
	<brief_title>A Research Study Patients With End-Stage Renal Disease ( ESRD )</brief_title>
	<detailed_description />
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Kidney Failure , Chronic</mesh_term>
	<mesh_term>Renal Insufficiency , Chronic</mesh_term>
	<mesh_term>Cinacalcet Hydrochloride</mesh_term>
	<criteria>ESRD patient require maintenance dialysis ( haemodialysis , haemodiafiltration , haemofiltration , peritoneal dialysis ) least 1 month The mean 2 iPTH determination within 21 day randomization draw least 2 day apart must great equal 300 pg/mL ( 31.8 pmol/L ) less 800 pg/mL ( 84.8 pmol/L ) . If biPTH determine , mean level must great equal 150 pg/mL ( 15.9 pmol/L ) less 410 pg/mL ( 43.5 pmol/L ) The mean 2 serum calcium determination ( correct albumin ) drawn day PTH determination must great equal 8.4 mg/dL ( 2.1 mmol/L ) Have unstable medical condition , define hospitalise , dialysis vascular access revision , within 30 day day 1 , otherwise unstable judgment investigator Have parathyroidectomy 6 month day 1 Have receive vitamin D therapy le 21 day day 1 require change prescribe vitamin D brand dose within 21 day day 1 . If subject prescribe vitamin D therapy , must remain free vitamin D therapy 21 day day 1 . Received , within 21 day day 1 dose titration phase , therapy medication predominantly metabolize enzyme CYP2D6 narrow therapeutic index ( e.g. , flecainide , vinblastine , thioridazine , tricyclic antidepressant ) . The tricyclic antidepressant amitriptyline permit . Experienced myocardial infarction within 3 month prior day 1 Are currently enrol , yet complete least 30 day day 1 , invasive investigational device investigational drug trial , receive investigational agent ( experimental dialysis machine acceptable ) Have gastrointestinal disorder may associate impaired absorption orally administer medication inability swallow tablet</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2011</verification_date>
	<keyword>Secondary HyperParaThyroidism ( SHPT )</keyword>
	<keyword>Dialysis , End Stage Renal Disease ( ESRD )</keyword>
	<keyword>KDOQI , Cinacalcet</keyword>
	<keyword>Clinical Trial , Amgen</keyword>
</DOC>